Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer

2022372 citationsJournal Articlegold Open Access

Authors

Lanxiang Huang · Zhongnan Hospital of Wuhan University

Yuan Rong · Zhongnan Hospital of Wuhan University

Xuan Tang · Zhongnan Hospital of Wuhan University

Kezhen Yi · Zhongnan Hospital of Wuhan University

Peng Qi · Jianghan University

Jinxuan Hou · Zhongnan Hospital of Wuhan University

Weihuang Liu

Abstract

DCs: dendritic cells; α-LA: α-lactalbumin; HELA-Exos: Hiltonol-ELANE-α-LA-engineered exosomes; ICD: immunogenic cell death; ELANE: human neutrophil elastase; TLR3: Toll-like receptor 3; TNBC: triple-negative breast cancer; TME: tumor microenvironment; DAMPs: damage-associated molecular patterns; cDC1s: type 1 conventional dendritic cells; PBMCs: peripheral blood mononuclear cells.

Topics & Keywords

Immunotherapy and Immune Responses Extracellular vesicles in disease RNA Interference and Gene Delivery

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Molecular Cancer

Volume 21, Issue 1, pp. 45-45

DOI: 10.1186/s12943-022-01515-x

Field-Weighted Citation Impact: 28.99